The genetic disorder known as Progeria causes premature aging. Children suffering from the disorder look like eighty-year-olds, dying of heart attacks and stroke by the time they are teens.
Eminent geneticist Gordon Harris of Boston General has discovered a breakthrough treatment for Progeria, but the National Institute of Health just refused to renew his grant request. Hoping to secure a new source of funding, he approaches Celestica, a Swiss-based pharmaceutical company.
Celestica finds Harris's research intriguing. He's devised a treatment that effectively arrests the aging process. Not sharing Harris's concern for the one in a million children suffering from Progeria, the company plans to mass-market the new drug as an age-inhibitor, charging a premium price to those who can afford it. They name Harris's new treatment Juvena, after the Roman god of youth.
When Harris refuses to cooperate, he discovers just how far Celestica will go to protect company profits. Threatened, kidnapped, and framed for murder, the geneticist finds himself battling the international conglomerate, while Celestica obscures important information to secure FDA approval for Juvena.
Celestica doesn't want the public to know that Juvena has just one significant side effect: once you start taking it, you can't stop—not if you want to keep breathing.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Allan Zelinger is a practicing cardiologist who received training in Boston, Massachusetts. His experience in medicine coupled with an interest in the science of aging forms the foundation of his current novel. The Juvena Project is the second book in his Boston General medical thriller trilogy, which began with Vital Organs.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : World of Books (was SecondSale), Montgomery, IL, Etats-Unis
Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc. N° de réf. du vendeur 00065072675
Quantité disponible : 1 disponible(s)
Vendeur : HPB Inc., Dallas, TX, Etats-Unis
paperback. Etat : Very Good. Connecting readers with great books since 1972! Used books may not include companion materials, and may have some shelf wear or limited writing. We ship orders daily and Customer Service is our top priority! N° de réf. du vendeur S_424303288
Quantité disponible : 1 disponible(s)
Vendeur : ThriftBooks-Atlanta, AUSTELL, GA, Etats-Unis
Paperback. Etat : Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less. N° de réf. du vendeur G1496124278I4N00
Quantité disponible : 1 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 21703259
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 21703259-n
Quantité disponible : Plus de 20 disponibles
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. Print on Demand. N° de réf. du vendeur I-9781496124272
Quantité disponible : Plus de 20 disponibles
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Paperback / softback. Etat : New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days. N° de réf. du vendeur C9781496124272
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 21703259
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : New. N° de réf. du vendeur 21703259-n
Quantité disponible : Plus de 20 disponibles
Vendeur : CitiRetail, Stevenage, Royaume-Uni
Paperback. Etat : new. Paperback. The genetic disorder known as Progeria causes premature aging. Children suffering from the disorder look like eighty-year-olds, dying of heart attacks and stroke by the time they are teens. Eminent geneticist Gordon Harris of Boston General has discovered a breakthrough treatment for Progeria, but the National Institute of Health just refused to renew his grant request. Hoping to secure a new source of funding, he approaches Celestica, a Swiss-based pharmaceutical company. Celestica finds Harris's research intriguing. He's devised a treatment that effectively arrests the aging process. Not sharing Harris's concern for the one in a million children suffering from Progeria, the company plans to mass-market the new drug as an age-inhibitor, charging a premium price to those who can afford it. They name Harris's new treatment Juvena, after the Roman god of youth. When Harris refuses to cooperate, he discovers just how far Celestica will go to protect company profits. Threatened, kidnapped, and framed for murder, the geneticist finds himself battling the international conglomerate, while Celestica obscures important information to secure FDA approval for Juvena. Celestica doesn't want the public to know that Juvena has just one significant side effect: once you start taking it, you can't stop-not if you want to keep breathing. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9781496124272
Quantité disponible : 1 disponible(s)